Turn Therapeutics discloses $1.65 million equity raise in Form D filing
The Westlake Village biotechnology company reported sales to eight investors under a Rule 506(b) exemption, with first sale dated August 14, 2026.
Turn Therapeutics Inc., operating under filer Global Health Solutions, Inc., submitted a Form D notice to the Securities and Exchange Commission dated August 26, 2026, disclosing an exempt securities offering. The filing marks a new notice with a date of first sale of 2026-08-14.1
The company reported a total amount sold of $1,650,0001, with the total offering amount and remaining amount to be sold both listed as indefinite. The total number of investors who have already invested in the offering was listed as 8.1
The securities offered are equity.1 The minimum investment accepted from any outside investor was set at $15,000.1 The company claimed the Rule 506(b) exemption under Regulation D.1
The filing listed sales commissions and finders' fees both at $0.1 The amount of proceeds proposed for payments to executive officers, directors, or promoters was also listed at $0.1
The issuer is identified as Turn Therapeutics Inc., a Delaware corporation based at 250 North Westlake Blvd. in Westlake Village, California.1 The company classified itself under the biotechnology industry group.1
Related persons named in the filing include Bradley Burnam and Neilesh Shailesh Ghodadra, both listed as executive officers and directors, along with Zuraiz Chaudhary as an executive officer, and directors Martin William Dewhurst, Andrew Gengos, Arthur F. Golden, and Kent Kester1. The notice was signed by Zuraiz Chaudhary, listed as VP Finance & Chief Accounting Officer, on 2026-08-261.
The filing does not specify further use of proceeds or additional details on the offering's purpose.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.